TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in Liking of E-cigarette Overall
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Liking of E-cigarette Flavor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median Time to Minimal Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Clinical Response at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of Paraoxonase Serum and BAL Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in clinical attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with an etiological diagnosis of Uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenylalanine excretion (F13CO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Phenylalanine oxidation (PheOX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ease of IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IgG GMCs ratio at 1-month post boost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With EBS Clinical Remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite rate of ICU-acquired MRSA or VRE infections
Endpoint domain: Adverse events/effects
Primary endpoint: Anterior Chamber Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cionni Ring Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from the posterior surface of iris and ciliary body region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With GI Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Accuracy of endoscopic assessment in predicting pT0 urothelial disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Caesarean Section (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of neonates requiring intensive care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of A4250 after a high fat meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time zero extrapolated to infinity (AUC (0-inf)) of A4250 after a high fat meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time zero to last measurable concentration (AUC(0-t)) of A4250 after a high fat meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lag Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of muscle atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Functional testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about epilepsy change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Skill about epileptic seizure time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kneecap displacement (knee laxity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mortality post-procedure
Endpoint domain: Mortality/survival
Primary endpoint: Cytokine concentration difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Score on Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Score on the Timed Up and Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable physiologic states
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate Post Polypectomy Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of helicobacter pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Urinary frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of Urge score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of total score of OAB-q (Overactive Bladder questionnaire) long form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Opioid Consumption in a 24-Hour period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PROMIS completion rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of routine care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days alive and out of hospital
Endpoint domain: Mortality/survival
Primary endpoint: Safety of BPX-501
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of Rimiducid
Endpoint domain: Adverse events/effects
Primary endpoint: Total Score From the Full Men's Sexual Health Questionnaire (MSHQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Liver free of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-reported physical activity level of one week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objectively assessed physical activity level of one week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum glycosylated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart rate recovery step test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effectiveness of chest physiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Patients With a Disease Progression Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pre-existing Pruritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Podological grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma pharmacokinetic parameters: AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pharmacokinetic parameters: Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of reoperation due to burst abdomen
Endpoint domain: Adverse events/effects
Primary endpoint: Next intervention free survival (FIFS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of urological
Endpoint domain: Adverse events/effects
Primary endpoint: Pre-specified Infusion Associated Events Within 6 Hours
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac Arrest or Death Within 24 Hours
Endpoint domain: Mortality/survival
Primary endpoint: Unexpected Severe Adverse Events (Including All-cause Deaths)
Endpoint domain: Adverse events/effects
Primary endpoint: Dental Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective beneficial effects on dry eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who meet exercise recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of Litx™ therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Zone of tumor destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Illicit drug use
Endpoint domain: Adverse events/effects
Primary endpoint: mean duration until complete fetal expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Age of diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathological nodal involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with NAFLD without advanced fibrosis and severe steatosis with portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with NAFLD and advanced fibrosis with portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Threshold of portal hypertension leading to portal hypertension-related complications in patients with NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: sperm retrieval rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: change of SPPB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Severe (Grade 4) Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in amygdala response to fearful faces stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in amygdala response to fear conditioning task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in ventromedial prefrontal cortex (vmPFC) activation during the fear extinction task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(O-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference change on the number of embryos to be transferred
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Agreement in VAS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of RSV challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Laxity Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical efficacy of Etanercept mouthwash
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in liver fat content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fluorescein leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: plasma TNFalpha concentration (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under Plasma Concentration-time for Caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival to cardiac transplantation or to 180 days post implantation
Endpoint domain: Mortality/survival
Primary endpoint: Beta Cell Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DASH - the Disabilities of the Arm, Shoulder and Hand
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of pulmonary capillary wedge pressure (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antitumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of New Osteoporotic Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patient Health Questionnaire (PHQ9)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Generalised Anxiety Disorder Questionnaire (GAD7)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Macular thickness by OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Explicit memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Days to reach Oral intake status level 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to total oral intake within 21 days post extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pass or fail Three-Step Swallowing Screen at 21st day post-extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anatomic lower limb length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell-mediated immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in information omissions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Waist/Hip Ratio (WHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Major Complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Interleukin 6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adenosine Triphosphate (ATP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recovery of motor function post stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Anxiety Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients with and severity of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Dose interruptions and reductions
Endpoint domain: Adverse events/effects
Primary endpoint: Arterial thromboembolic events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Occurrences of Mild, Moderate, or Severe Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With >=1 Mild, Moderate, or Severe Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of Patients With T Cell Inflammation in the Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Subjects With at Least One Episode of Shigellosis
Endpoint domain: Adverse events/effects
Primary endpoint: 12 Month-progression-free Survival for Participants With Anaplastic Tumors
Endpoint domain: Mortality/survival
Primary endpoint: 6 Month Progression-free Survival for Participants With Glioblastoma
Endpoint domain: Mortality/survival
Primary endpoint: Composite endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Disability level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Extent of coronary artery disease (Gensini and SYNTAX score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of copies of Wilms' Tumor 1 (WT1) antigen expression in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of copies of PRAME (Preferentially expressed in melanoma) antigen expression in bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of ACN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Asthma Control Questionnaire (ACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microvascular Flow Index (MFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Perfused Vessels (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Perfused Vessel Density (PVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GTV (cm³)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of contoured lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean esophagus dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Medication Possession Ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean Belatacept Serum Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in anterior chamber
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Blood level distributions of methylated DNA tumor markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Detection of cancer using urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Renin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Aldosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Pro-BNP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptance and Action Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comprehensive Assessment of Acceptance and Commitment Therapy (CompACT)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Five Facet of Mindfulness Questionnaire (FFMQ) - SHORT FORM
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical score of respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Onset of Psychosis
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Achieved Freedom From Atrial Tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Primary Adverse Events Within Specified Study Period
Endpoint domain: Adverse events/effects
Primary endpoint: 3-year disease specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of H pylori eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: late coronary lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline Fugl-Meyer motor assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device related and unanticipated serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics profile of exenatide (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of product
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Voice Handicap Index - 10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clavien Dindo Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Successful repair of conduit disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IPV positive
Endpoint domain: Adverse events/effects
Primary endpoint: Screening completed
Endpoint domain: Resource use
Primary endpoint: Clinical cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of spontaneous UCP-specific Th1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in HOMA from baseline to 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in OGTT from baseline to 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes